TY - JOUR
T1 - Antiviral antibody responses to systemic administration of an oncolytic RNA virus
T2 - The impact of standard concomitant anticancer chemotherapies
AU - Roulstone, Victoria
AU - Mansfield, David
AU - Harris, Robert J.
AU - Twigger, Katie
AU - White, Christine
AU - de Bono, Johann
AU - Spicer, James
AU - Karagiannis, Sophia N.
AU - Vile, Richard
AU - Pandha, Hardev
AU - Melcher, Alan
AU - Harrington, Kevin
N1 - Publisher Copyright:
© Author(s) (or their employer(s)) 2021. Re-use permitted under CC BY. Published by BMJ.
PY - 2021/7/22
Y1 - 2021/7/22
N2 - Oncolytic reovirus therapy for cancer induces a typical antiviral response to this RNA virus, including neutralizing antibodies. Concomitant treatment with cytotoxic chemotherapies has been hypothesized to improve the therapeutic potential of the virus. Chemotherapy side effects can include immunosuppression, which may slow the rate of the antiviral antibody response, as well as potentially make the patient more vulnerable to viral infection. Reovirus neutralizing antibody data were aggregated from separate phase I clinical trials of reovirus administered as a single agent or in combination with gemcitabine, docetaxel, carboplatin and paclitaxel doublet or cyclophosphamide. In addition, the kinetics of individual antibody isotypes were profiled in sera collected in these trials. These data demonstrate preserved antiviral antibody responses, with only moderately reduced kinetics with some drugs, most notably gemcitabine. All patients ultimately produced an effective neutralizing antibody response. Patients’ responses to infection by reovirus are largely unaffected by the concomitant drug treatments tested, providing confidence that RNA viral treatment or infection is compatible with standard of care treatments.
AB - Oncolytic reovirus therapy for cancer induces a typical antiviral response to this RNA virus, including neutralizing antibodies. Concomitant treatment with cytotoxic chemotherapies has been hypothesized to improve the therapeutic potential of the virus. Chemotherapy side effects can include immunosuppression, which may slow the rate of the antiviral antibody response, as well as potentially make the patient more vulnerable to viral infection. Reovirus neutralizing antibody data were aggregated from separate phase I clinical trials of reovirus administered as a single agent or in combination with gemcitabine, docetaxel, carboplatin and paclitaxel doublet or cyclophosphamide. In addition, the kinetics of individual antibody isotypes were profiled in sera collected in these trials. These data demonstrate preserved antiviral antibody responses, with only moderately reduced kinetics with some drugs, most notably gemcitabine. All patients ultimately produced an effective neutralizing antibody response. Patients’ responses to infection by reovirus are largely unaffected by the concomitant drug treatments tested, providing confidence that RNA viral treatment or infection is compatible with standard of care treatments.
KW - humoral
KW - immunity
KW - immunomodulation
KW - oncolytic virotherapy
KW - oncolytic viruses
UR - http://www.scopus.com/inward/record.url?scp=85111455492&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85111455492&partnerID=8YFLogxK
U2 - 10.1136/jitc-2021-002673
DO - 10.1136/jitc-2021-002673
M3 - Article
C2 - 34301814
AN - SCOPUS:85111455492
SN - 2051-1426
VL - 9
JO - Journal for ImmunoTherapy of Cancer
JF - Journal for ImmunoTherapy of Cancer
IS - 7
M1 - e002673
ER -